


Servier factsheet

Founded to serve health, Servier is a global pharmaceutical group governed by a non-profit Foundation. We aspire to have a meaningful social impact, both for patients and for a sustainable world. This unique governance model enables us to fully serve our vocation with a long-term vision: being committed to therapeutic progress to serve patient needs.



*IQVIA, Analytics Link / World 75 countries – MAT Q3-2024





Our therapeutic areas



With an extensive range of brand-name and generic medicines, Servier helps to treat patients in over 150 countries.

Oncology

Cancer is the second leading cause of death in the world^{*} and numbers are on the rise. To address the growing need for therapeutic solutions, we have made oncology and in particular hard-to-treat cancers a priority focus for development.

Cardiometabolism and venous diseases

We intend to maintain our leading position in this area by taking a strategic and innovative approach to managing the life cycle of our medicines in particular by developing *Single Pill Combinations* (SPC: treatments that combine several active ingredients in a single pill)

Neuroscience

We focus our R&D efforts on developing new medicines that slow the progression of rare diseases or diseases with a genetic origin that affect sub-populations of patients.

Immuno-inflammation

We develop targeted therapies to correct the inappropriate immune response through different approaches such as: ⇒ targeting a protein that plays a role in the pathology ⇒ targeting various adaptive immune system mechanisms, which could stop the production of autoantibodies that drive disease.

*Source : WHO



The strategy we defined for the period through to 2030 is both realistic and bold. It addresses the health challenges of today and tomorrow and fulfils our vocation as a Group committed to therapeutic progress to serve patient needs.

BY 2030, SERVIER AIMS TO BE:



An innovative and patient-driven company with a rich pipeline

A resilient, growing and highly profitable company, balanced across three pillars: oncology, neuroscience & immuno-inflammation, cardiometabolism & venous diseases, and Generics

A company with a measurable positive social impact



An attractive company, with proud and passionate employees

OUR AMBITION IS UNDERPINNED BY THE FOLLOWING TARGETS:

